GlaxoSmithKline
Although Glaxo touts a diverse drug portfolio, the company has to be shaking in its boots as two blockbusters are set to come off patent before 2012 ends.
The fourth-largest drug in the world, Seretide, is set to come off patent this year. Also known as Advair, this asthma treatment has thus far been incredibly difficult for generic competitors to duplicate. Perhaps one of the only saving graces for Glaxo is that it doesn't have any generic competitors lined up to eat into Advair's sales, which totaled $8.1 last year. But where there's a will, there's a way, and it's only a matter of time before a generic competitor to Advair hits the market.
Also coming off patent in 2012 is Glaxo's diabetes drug Avandia, which contributed more than $700 million in sales last year. Together, Avandia and Advair represent 24% of Glaxo's total revenues in 2010 and are a major reason Glaxo could be in trouble sooner rather than later.
Entradas
No hay comentarios:
Publicar un comentario